SPOTLIGHT: CellCept wins orphan status
The FDA has granted orphan drug status to the immunosuppressant CellCept, being developed by Roche and Aspreva. CellCept is currently in a late-stage trial for Myasthenia Gravis, a rare immune system ailment. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
